The incidence of pancreatic cancer（PC），as a highly invasive malignant tumor，is increasing both at home and abroad annually. For patients with no indication of surgical treatment，targeted therapy has obvi⁃ ous advantages. The biological behaviors of tumor cells such as proliferation，apoptosis and angiogenesis are regu⁃ lated by the phosphatidylinositol 3 kinase（PI3K）signaling pathway，and the use of PI3K inhibitors can improve the prognosis of patients. Inhibitors of the PI3K signaling pathway include those targeting a single component and dual or multiple inhibitors. At present，PI3K⁃targeted inhibitors have achieved good results in clinical trials of lym⁃ phoid hematopoietic tumors and other solid tumors，but there are few studies on pancreatic cancer. For this reason， we briefly review the research progress of PI3K pathway，summarizing the new advances of inhibitors targeting PI3K signaling pathway in the treatment of pancreatic cancer.